RTU Research Information System
Latviešu English

Publikācija: Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles

Publication Type Scientific article indexed in SCOPUS or WOS database
Funding for basic activity Unknown
Defending: ,
Publication language English (en)
Title in original language Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles
Field of research 1. Natural sciences
Sub-field of research 1.3 Physical sciences
Authors Dace Skrastina
Ivars Petrovskis
Ilva Lieknina
Janis Bogans
Regīna Renhofa
Velta Ose
Andris Dishlers
Jurijs Dehtjars
Pauls Pumpēns
Keywords nanoparticles , adjuvant virus like particle
Abstract Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10–20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund’s adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40%of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBcderived virus-like particles as the biological component.
DOI: 10.1371/journal.pone.0114006
Hyperlink: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0114006 
Reference Skrastina, D., Petrovskis, I., Lieknina, I., Bogans, J., Renhofa, R., Ose, V., Dishlers, A., Dehtjars, J., Pumpens, P. Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles. PLoS ONE, 2014, Vol.9, No.12, pp.1-17. ISSN 1932-6203. Available from: doi:10.1371/journal.pone.0114006
Additional information Citation count:
ID 19745